BMJ Open  Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents

Karen S W Leong,1,2 Thilini N Jayasinghe,1 José G B Derraik,1,2 Benjamín B Albert,3† Valentina Chiavaroli,1,6 Darren M Svirskis,3 Kathryn L Beck,4 Cathryn A Conlon,4 Yannan Jiang,5 William Schierding,1 Tommi Vatanen,1,6 David J Holland,7 Justin M O’Sullivan,1,2 Wayne S Cutfield1,2

ABSTRACT

Introduction Animal studies showed that germ-free mice inoculated with normal mouse gut bacteria developed obesity, insulin resistance and higher triglyceride levels, despite similar food intake. In humans, an association has been found between obesity and gut microbiome dysbiosis. However, gut microbiome transfer has not been evaluated for the treatment of human obesity. We will examine the effectiveness of gut microbiome transfer using encapsulated material for the treatment of obesity in adolescents.

Methods and analysis A two-arm, double-blind, placebo-controlled, randomised clinical trial of a single course of gut microbiome transfer will be conducted in 80 obese (body mass index (BMI) ≥30 kg/m²) adolescents (males and females, aged 14–18 years) in Auckland, New Zealand. Healthy lean donors (males and females, aged 18–28 years) will provide fresh stool samples from which bacteria will be isolated and double encapsulated. Participants (recipients) will be randomised at 1:1 to control (placebo) or treatment (gut microbiome transfer), stratified by sex. Recipients will receive 28 capsules over two consecutive mornings (∼14 mL of frozen microbial suspension or saline). Clinical assessments will be performed at baseline, 6, 12 and 26 weeks, and will include: anthropometry, blood pressure, fasting metabolic markers, dietary intake, physical activity levels and health-related quality of life. Insulin sensitivity (Matsuda index), gut microbiota population structure characterised by 16S rRNA amplicon sequencing and body composition (using dual-energy X-ray absorptiometry) will be assessed at baseline, 6, 12 and 26 weeks. 24-hour ambulatory blood pressure monitoring will be performed at baseline and 6 weeks. The primary outcome is BMI SD scores (SDS) at 6 weeks, with BMI SDS at 12 and 26 weeks as secondary outcomes. Other secondary outcomes include insulin sensitivity, adiposity (total body fat percentage) and gut microbial composition at 6, 12 and 26 weeks. Statistical analysis will be performed on the principle of intention to treat.

Strengths and limitations of this study

This is the largest registered randomised clinical trial of gut microbiome transfer for obesity or insulin resistance in children or adults.

The double-blind, placebo-controlled design, use of capsules as a non-invasive method of delivery, and characterisation of bacterial diversity and viability in donor stools are main strengths of this randomised clinical trial.

Conducting a 6-month follow-up after a single treatment with gut microbiome will allow identification of a possible lag between treatment and change in body mass index (BMI).

This study is adequately powered to show a meaningful reduction in BMI SD scores in the treated group.

Our study will focus on obese adolescents, so that the findings may not be readily extrapolated to individual with lesser degrees of adiposity or to older adults.

Ethics and dissemination Ethics approval was provided by the Northern A Health and Disability Ethics Committee (Ministry of Health, New Zealand; 16/NTA/172). The trial results will be published in peer-reviewed journals and presented at international conferences.

Trial registration number ACTRN12615001351505; Pre-results.

INTRODUCTION

There is an increasing prevalence of obesity among children and adolescents.1 Obesity tracks and amplifies through life,2,3 and childhood obesity is associated with even greater severity of obesity and related comorbidities in adulthood.4,5 An elevated body mass index (BMI) in adolescence is associated with...
increased all-cause mortality in adult life, and it is more predictive of later mortality than an elevated adult BMI.\(^5\)\(^6\)

New paradigms on the causes of obesity incorporate a pivotal role for the gut microbiota (ie, the microbial community present in the gastrointestinal tract). In recent years, assessments of the gut microbiome (all of the genes inside these gut microbiota cells) have identified reduced diversity of bacterial taxa as having an important effect on the development of obesity, insulin resistance and diabetes mellitus.\(^7\)\(^8\) The concept that the gut microbiome influences host metabolism and adiposity was introduced through gut microbiome transfer experiments in gnotobiotic (ie, germ-free) mice.\(^9\)\(^10\) These gnotobiotic mice have sterile colons and 40% less body fat than conventional mice, despite a food intake that is 29% higher.\(^9\) When germ-free mice were inoculated with normal mouse gut bacteria, they developed obesity, insulin resistance and increased triglycerides levels, while on the same food intake.\(^11\)

Further experiments showed that the gut microbiome modulates both sides of the energy balance equation by: (1) increasing energy yield from the diet stored as triglycerides and (2) altering energy expenditure via fatty acid oxidation.\(^10\)\(^12\)\(^13\) These effects occur either directly within the bowel, or indirectly through the effects of bacterial products that enter the circulation. Current literature indicates that changes to the gut microbiome and their respective products within the host circulation (eg, lipopolysaccharides and short-chain fatty acids) can alter host responses, modulate insulin resistance, adiposity, and atherosclerosis and have an effect on the development of non-alcoholic fatty liver disease.\(^14\)\(^15\)

Gut microbiome transfer is now regularly used to treat recurrent or refractory *Clostridium difficile* colitis, which is associated with considerable morbidity and a reported 38% mortality.\(^16\) Other treatment regimens for this disorder have relied on repeated courses of vancomycin, typically with low cure rates (~31%).\(^17\) By contrast, a single nasoduodenal infusion of a ‘healthy’ gut microbiome in elderly patients with chronic *C. difficile* colitis led to cure in 81% of subjects.\(^17\) This and other studies\(^18\)\(^19\)\(^20\) have demonstrated that gut microbiome transfer is a viable treatment option for recurrent or refractory *C. difficile* colitis, without any noticeable side effects. Studies have confirmed that 6 weeks after gut microbiome transfer, the recipient’s gut microbiome population structure resembles that of the donor.\(^21\)

Gut microbiome transfer is a possible treatment for obesity and metabolic syndrome.\(^22\)\(^23\) To date, investigation of the therapeutic benefit of gut microbiome transfer in adult metabolic disease (obesity and metabolic syndrome) has been limited.\(^20\) Vrieze et al performed a short-term gut microbiome transfer study in nine treated and nine control middle-aged adults with metabolic syndrome.\(^20\) Six weeks after gut microbiome transfer via nasoduodenal tube, treated recipients had an impressive 75% improvement in insulin sensitivity. Kootte et al reported similar results at 6 weeks among 38 obese males (median age 56 years), but the improvements in both insulin sensitivity and gut microbiota composition reverted back to baseline at 18 weeks.\(^23\) Conversely, our group (unpublished data) demonstrated that gut microbiome composition in recipients changed after gut microbiome transfer to mimic the lean donor’s gut microbiome, and that this effect was sustained 26 weeks after treatment. This indirectly indicates that it is possible to change the gut microbiome, using a healthy donor, with possible concurrent health benefits.

Selection of donors is critical for successful gut microbiome transfer. The adverse effect of an inappropriate donor was illustrated by a patient with chronic *C. difficile* colitis, who developed new-onset obesity following gut microbiome transfer from a healthy but overweight donor.\(^24\) Notably, a similar result was observed when the microbiome from an obese human was transferred into a lean mouse.\(^25\)

Gut microbiome transfer is not considered a probiotic treatment.\(^20\) Although gut microbiome transfer and probiotics involve the administration of live bacteria, this is where the similarities end. Probiotics are one of several defined live bacterial strains (eg, *Bifidobacterium adolescentis, Lactobacillus acidophilus* and *Lactobacillus casei*) that have been previously isolated and characterised.\(^26\) The rationale for this treatment is that these supplemental bacteria and products have been shown to confer general health benefits. Conversely, gut microbiome transfer consists of transferring the entire microbiome from a healthy donor to a recipient, in order to establish a healthier microbial community and ameliorate the undesirable underlying condition. Meta-analyses of randomised controlled studies of the effects of probiotics (eg, *Lactobacillus* spp and fermented milk-based probiotic treatments) on weight loss are conflicting.\(^27\)\(^28\) There are currently no published studies of gut microbiome transfer for the treatment of human obesity. However, a study has shown that germ-free mice lose weight following gut microbiome transfer from mice who had gastric bypass surgery and exhibited rapid weight loss.\(^29\) In addition, meta-analyses of the effectiveness of microbial transfers in the treatment of *C. difficile*\(^20\) have demonstrated that gut microbiome transfer is efficacious and safe for inflammatory bowel disease (pooled cure rate 36%; 95% CI 17% to 60%).\(^31\)\(^32\) and *C. difficile* (pooled cure rate 89%; 95% CI 84% to 93%).\(^30\) As such, gut microbiome transfer holds significant promise as a treatment for the rapid and concerted modification of an unhealthy gut microbiome, which we hypothesise will lead to weight loss in obese humans.

This clinical trial will assess whether gut microbiome transfer using encapsulated material is an effective treatment for obesity in adolescents.

**METHODS AND ANALYSIS**

**Study design**

This study is a two-arm, double-blind, placebo-controlled, randomised clinical trial with obese adolescents randomly assigned to either treatment (encapsulated gut microbiome) or placebo (encapsulated saline solution), stratified by sex. Eligible participants will be followed for 26 weeks. Participants are randomised using a random number generator. The study stratifies participants based on sex, with a 2:1 ratio of females to males to ensure more female patients than males. The primary endpoint is weight loss measured as both absolute and percentage change from baseline to 26 weeks. A secondary endpoint is the number of patients achieving a 5% or greater absolute weight loss. Other secondary endpoints of interest include changes in body mass index, waist circumference, body fat percentage, and fasting blood glucose and insulin levels.

**Inclusion criteria**

- Age 10 to 18 years old
- Body mass index (BMI) > 30 kg/m²
- Availability to attend the study centre weekly for the duration of the study
- Ability to give informed consent

**Exclusion criteria**

- Any acute or chronic illness, including but not limited to gastrointestinal disorders, that may affect weight gain or loss
- Any condition that may interfere with the patient’s ability to participate in the study
- Any condition that may interfere with the patient’s ability to give informed consent
- Any condition that may interfere with the patient’s ability to follow the study protocol

**Randomisation**

Participants are randomised using a random number generator. The study stratifies participants based on sex, with a 2:1 ratio of females to males to ensure more female patients than males.

**Blinding**

This study is a double-blind, placebo-controlled trial. The participants and the researchers who assess the outcomes are blinded to the treatment groups. The study team who interacts with the participants is also blinded to the treatment groups.

**Endpoints**

- Primary endpoint: weight loss measured as both absolute and percentage change from baseline to 26 weeks.
- Secondary endpoints: changes in body mass index, waist circumference, body fat percentage, and fasting blood glucose and insulin levels.

**Data analysis**

The data will be analysed using appropriate statistical methods. The primary endpoint will be analysed using an intention-to-treat analysis, which includes all participants who were randomised and received at least one dose of the assigned treatment. The secondary endpoints will be analysed using a mixed-effects model for repeated measures.

**Ethical considerations**

The study is approved by the local ethics committee. All participants will provide informed consent. The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
weeks after randomisation (figure 1). This trial protocol is reported as per the SPIRIT guidelines.32

Recruitment and eligibility criteria

Donors

We will recruit eight donors (four males and four females), as recipients will only receive gut microbiome from donors of the same sex. This is to enhance microbial variability and standardise the treatment via gut microbiome transfer. Treatment with gut microbiome from donors of the same sex will be done as there may be potentially sex-specific differences in the effect of gut microbiome on weight and metabolism as described by Markle et al.33 Donors will be selected following strict inclusion criteria as described in table 1, with exclusion criteria adapted from Youngster et al, Hirsch et al, van Nood et al and Bakken et al.17–19 34 Eligible donors will be identified by word of mouth, the internal email system at the University of Auckland and social media networks. Potential donors will be given a detailed information sheet about the study that includes a consent form.

To eliminate the risks of transmission of infectious diseases, we will use screening procedures equivalent to those used for blood donation in New Zealand,35 and also screen donors for potential faecal pathogens or multidrug-resistant organisms. As part of this regimen, all potential donors will undergo extensive testing for human pathogens, antigens and antibodies (that indicate exposure to hepatitis A, B or C viruses and HIV), syphilis, C. difficile, Helicobacter pylori, other bacterial and viral pathogens, multidrug-resistant organisms, as well as intestinal parasites. We will supplement these microbiological tests with characterisation of the gut microbiome through analysis of the metagenome and metatranscriptome.36 In addition, we will conduct an interview to gather information about behaviours or activities that may exclude them from the trial (table 1).

Table 1 Inclusion and exclusion criteria for donors in the Gut Bugs Trial

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aged 18–28 years</td>
<td>Any transmissible viral or bacterial pathogens, or intestinal parasites.</td>
</tr>
<tr>
<td>Body mass index &gt;18.5 kg/m² and &lt;30.0 kg/m²</td>
<td>Multidrug-resistant organisms (eg, vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae).</td>
</tr>
<tr>
<td>Total body fat ≤29% for females and ≤19% for males.</td>
<td>Gastrointestinal disease (including symptoms of irritable bowel syndrome, inflammatory bowel disease or coeliac disease).</td>
</tr>
<tr>
<td>Regular exercise (moderate to vigorous physical activity for at least 3.5 hours per week).</td>
<td>Atopic diseases requiring regular prophylaxis or treatment.</td>
</tr>
<tr>
<td>Regular bowel habit (at least once every 2 days).</td>
<td>Current or past history of malignancy.</td>
</tr>
<tr>
<td>Intake of ≥4 portions of fruit and/or vegetables per day.</td>
<td>Impaired fasting glucose or impaired glucose tolerance.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria adapted from Youngster et al, Hirsch et al, van Nood et al and Bakken et al.17–19 34</th>
<th>Type 1 diabetes, type 2 diabetes or monogenic diabetes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known dyslipidaemia, hypertension or metabolic syndrome.</td>
<td>Use of oral antibiotics in the past 3 months.</td>
</tr>
<tr>
<td>Regular use of medications known to influence metabolism or the gut microbiome.</td>
<td>Regular ‘binge drinking’, that is, consumption of 5 or more standard drinks of alcohol per session, at least once a week.</td>
</tr>
<tr>
<td>Use of recreational drugs or tobacco.</td>
<td>Any use of recreational drugs or tobacco.</td>
</tr>
<tr>
<td>Current or past pregnancy.</td>
<td>Current or past pregnancy.</td>
</tr>
<tr>
<td>Overseas travel in previous 6 months, except for visits to Australia, UK, USA, Canada, Northern Europe, France and Germany.</td>
<td>UK residence in 1980–1996 (due to risk of variant Creutzfeldt-Jakob disease).</td>
</tr>
</tbody>
</table>

Exclusion criteria adapted from Youngster et al, Hirsch et al, van Nood et al and Bakken et al.17–19 34

Figure 1 Diagram showing flow of participants (recipients) in the Gut Bugs Trial.
Given evidence that irritable bowel syndrome (IBS) may be related to the gut microbiome, it is important to exclude potential donors who may have IBS. The Rome criteria are an accepted clinical tool to identify individuals with IBS, but they are relatively insensitive so that strict adherence to those criteria would potentially allow for individuals with mild IBS to donate. Therefore, we will screen for IBS using a conservative modification of the Rome criteria, where we define a positive screen as having three or more episodes of abdominal pain per month as described in part I of the criteria, as well as an additional symptom as defined in part II.

Each donor is expected to produce a wet stool sample weighing 100–150 g. Our preliminary laboratory data indicate that an average stool sample from a donor will generate sufficient gut microbiome material for two same-sex recipients. Stool samples will be collected and immediately processed for encapsulation. Capsules from each sample will be individually coded, so that each recipient will receive an equal number of capsules (n = 7) from each of the four same-sex donors.

### Participants (recipients)

We will recruit 80 obese adolescents as per inclusion and exclusion criteria described in Table 2. Eligible recipients will be recruited via social media, word of mouth and paediatric endocrinology clinics in Auckland. Potential recipients and caregivers will be given a detailed information sheet about the study that includes a consent form. Consent will be obtained from recipients if they are aged ≥16 years and from their parents if aged <16 years. Younger recipients will also be asked to sign an assent form. All consent and/or assent will be obtained by the researchers prior to the recipient’s participation in the trial. All potential and enrolled recipients’ personal information are recorded and kept in a secure folder and only accessible to the researchers, in order to protect their confidentiality.

### Specimen collection

The donor gut microbiome will be double encapsulated and administered to recipients by the oral route, which delivers bacteria to the proximal bowel. Thus, we will not require the use of invasive techniques (ie, nasoduodenal tube) for gut microbiome transfer. Instead, gut microbiome transfer will be performed as per recent studies, which demonstrated that an encapsulated microbiome was a viable treatment option for recurrent or refractory *C. difficile* colitis, without noticeable side effects.

We have validated methods for gut microbiome isolation, preparation and double encapsulation as detailed by Youngster et al. Briefly, immediately after donation, stools are placed in normal saline, blended and sieved to remove particulate matter. Samples are then differentially centrifuged to isolate a bacterial pellet. The bacterial pellet is suspended in normal saline (containing 15% glycerol—a cryoprotectant) at 0.5 g wet weight/mL before being dispensed into size 0 DRcaps capsules (Capsugel, Sydney, Australia). The size 0 capsules are closed and secondarily sealed in size 00 DRcaps capsules. These capsules mask taste, odour and visual appearance, and are designed to remain intact during passage through the stomach, delivering their contents to the intestine.

Capsules are stored frozen at −80°C.

The use of low-speed centrifugation to pellet the bacterial cells is a feature of this methodology that reduces the risk of having free viruses included into the treatment capsules. Storage (−80°C, <175 days) of microbiome capsules provides time to complete rigorous safety testing using microbiological and microscopic analyses.

### Randomisation, allocation and blinding

Eligible participants will be randomised in a 1:1 ratio to either treatment or placebo group, stratified by sex, using block randomisation with variable block sizes of 2 and 4. Randomisation sequences will be computer-generated and overseen by the biostatistician. Researchers

---

| Inclusion | Aged 14–18 years.  
| Body mass index ≥30 kg/m².  
| Postpubertal (Tanner stage 5). |

| Exclusion | Gastrointestinal disease (including inflammatory bowel disease or coeliac disease).  
| Use of regular medications that may influence weight, metabolism or the gut microbiome (including oral oestrogen-containing contraceptives, antidepressants, glucose-lowering drugs, diet drugs, as well as inhaled, topical or oral steroids).  
| Consumption of probiotics.  
| Type 1 diabetes, type 2 diabetes or monogenic diabetes  
| Chronic diseases that could affect the primary outcome (other than obesity-related conditions).  
| Food allergies.  
| Allergy to macrogol (active ingredient in the bowel preparation product).  
| Allergy to any over-the-counter medication.  
| No antibiotic usage for 3 months prior to trial treatment. |
and participants will be blinded to capsule contents, both of which (placebo and gut microbiome) look identical (white).

There are three steps in the blinding and allocation process. First, the independent research nurse allocates the recipient to group A or B using the randomisation sequence. Second, the placebo and treatment capsule packs each have a unique code (assigned by the technician who encapsulated them). Lastly, the independent research nurse allocates the pack according to the unique code associated with the randomisation sequence.

To maintain the integrity of the trial evaluation, statistical analyses will be performed at the completion of the study on encoded data (ie, group A vs group B), so that the biostatistician will be blinded to treatment allocation. Recipients will be asked if they are able to identify the contents of capsules taken (ie, placebo or gut microbiome) at 6 weeks and 26 weeks. The effectiveness of treatment blinding will be assessed using the Bang’s Blinding Index (BBI). Blinding success will be determined by the thresholds of Moroz et al: unblinded (BBI ≤ −0.2), random guesses (−0.2 < BBI < 0.2) or opposite guesses (BBI ≥ 0.2).

Recipients will be unblinded in the case of any serious adverse events. These include ongoing gastrointestinal bleeding, severe vomiting and/or diarrhoea, treatment-related systemic infection, treatment-related severe allergic reaction, coma, collapse or death. Unblinding will be done by an independent researcher who did not have any prior contact with the recipient, who will be able to determine the individual’s treatment allocation.

**Study intervention**

All recipients will undergo bowel cleansing prior to treatment using an oral solution containing 70 g of Glyco-prep-C (active ingredient macrogol 3350) (Fresenius Kabi Australia, Mount Kuring-gai, Australia). Bowel cleansing reduces gut microbial population by 31-fold and markedly reduces bacterial diversity. This procedure was used to determine the individual’s treatment allocation.

To maintain the integrity of the trial evaluation, statistical analyses will be performed at the completion of the study on encoded data (ie, group A vs group B), so that the biostatistician will be blinded to treatment allocation. Recipients will be asked if they are able to identify the contents of capsules taken (ie, placebo or gut microbiome) at 6 weeks and 26 weeks. The effectiveness of treatment blinding will be assessed using the Bang’s Blinding Index (BBI). Blinding success will be determined by the thresholds of Moroz et al: unblinded (BBI ≤ −0.2), random guesses (−0.2 < BBI < 0.2) or opposite guesses (BBI ≥ 0.2).

Recipients will be unblinded in the case of any serious adverse events. These include ongoing gastrointestinal bleeding, severe vomiting and/or diarrhoea, treatment-related systemic infection, treatment-related severe allergic reaction, coma, collapse or death. Unblinding will be done by an independent researcher who did not have any prior contact with the recipient, who will be able to determine the individual’s treatment allocation.

**Study intervention**

All recipients will undergo bowel cleansing prior to treatment using an oral solution containing 70 g of Glyco-prep-C (active ingredient macrogol 3350) (Fresenius Kabi Australia, Mount Kuring-gai, Australia). Bowel cleansing reduces gut microbial population by 31-fold and markedly reduces bacterial diversity. This procedure was used to determine the individual’s treatment allocation.

To maintain the integrity of the trial evaluation, statistical analyses will be performed at the completion of the study on encoded data (ie, group A vs group B), so that the biostatistician will be blinded to treatment allocation. Recipients will be asked if they are able to identify the contents of capsules taken (ie, placebo or gut microbiome) at 6 weeks and 26 weeks. The effectiveness of treatment blinding will be assessed using the Bang’s Blinding Index (BBI). Blinding success will be determined by the thresholds of Moroz et al: unblinded (BBI ≤ −0.2), random guesses (−0.2 < BBI < 0.2) or opposite guesses (BBI ≥ 0.2).

Recipients will be unblinded in the case of any serious adverse events. These include ongoing gastrointestinal bleeding, severe vomiting and/or diarrhoea, treatment-related systemic infection, treatment-related severe allergic reaction, coma, collapse or death. Unblinding will be done by an independent researcher who did not have any prior contact with the recipient, who will be able to determine the individual’s treatment allocation.

**Data collection and follow-up**

**Timing of assessments**

Recipients will be assessed four times over the course of the study: at baseline, 6 weeks, 12 weeks and 26 weeks. Longitudinal follow-up over 26 weeks will establish the duration of the effect. The specific assessments that will be carried out at each time point are outlined in table 3. Treatment (ie, intake of capsules) will be administered within a week of the baseline assessment.

Clinical assessments will start between 07:00 and 09:00 hours at the Maurice and Agnes Paykel Clinical Research Unit (Liggins Institute, University of Auckland), after an overnight fast and no strenuous activity over the previous 24 hours.

All the recipients will be contacted and reminded of their follow-up visits via emails and text messages. Any recipient having difficulties to attend their assessment visit will be given the option to reschedule it to a suitable time.

**Insulin sensitivity and other blood tests**

Insulin sensitivity will be assessed in all recipients using the Matsuda index from a 75 g oral glucose tolerance test. Blood samples will be collected at −10, 0, 30, 60, 90 and 120 min for glucose and insulin measurements. The Matsuda index is highly correlated with the hyperinsulinaemic euglycaemic clamp (the gold-standard assessment of insulin sensitivity) and has excellent reproducibility during multiple measures. Other markers of glycaemic control will also be measured, namely homoeostasis model assessment of insulin resistance (HOMA-IR) and glycated haemoglobin (HbA1c).

**Other blood tests**

Fasting blood samples will be taken during the insulin sensitivity assessment to measure a number of other parameters. These will include markers of metabolic syndrome, such as uric acid, high-sensitivity C-reactive protein (hsCRP) and fasting lipids (ie, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides). Liver function will be assessed by measurement of gamma-glutamyl transferase, alkaline phosphatase, alanine aminotransferase and aspartate transaminase.

**Anthropometry and body composition**

Height will be measured to the nearest mm using a Harpenden stadiometer. Recipients will be asked to undo
any hairstyle that might interfere with the measurements; they will stand with their feet together, with their back straight, and their heels in the same upright plane as the back of the head. Gentle upward traction on the mastoid process will be applied to straighten out the spine. Weight will be measured on a weighing scale (WM206, Wedderburn, Auckland, New Zealand) to the nearest 10 g. For weight measurements, the scale will be placed on a solid level floor, with recipients stepping on it with both feet at its centre. Both height and weight will be measured three times and the median value used for analysis; recipients will also be asked to remove shoes and bulky clothing, and to empty their pockets of any objects. Both the scale and stadiometer at our clinical research unit are checked on a weekly basis using the appropriate standards.

BMI will be calculated and transformed into SD scores (SDS) adjusted for age and sex, based on WHO standards.51 Waist and hip circumference measurements will be performed three times and the median value used for analysis. Both measurements will be made to the nearest mm with a standard measuring tape parallel to the floor, which is placed snugly around the recipient but without compressing the skin.53 Body composition will be assessed using whole-body dual-energy X-ray absorptiometry (DXA, Lunar Prodigy and Lunar iDXA, GE Medical Systems, Chicago, Illinois, USA). Recipients will have all longitudinal body composition data collected on the same device.

### Blood pressure

Clinic resting systolic and diastolic blood pressures will be measured at all assessments using the same oscillometric digital blood pressure monitor (ri-champion N; Riester, Jüngingen, Germany) with an appropriately-sized cuff on the extended non-dominant arm. All measurements will

---

**Table 3** Timing of individual assessments in the Gut Bugs Trial

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Baseline</th>
<th>6 weeks</th>
<th>12 weeks</th>
<th>26 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Medical history and examination</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Anthropometry</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>DXA</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clinic blood pressure</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>24-hour ambulatory blood pressure monitoring</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Questionnaires</td>
<td>–</td>
<td>✓</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3-day dietary record</td>
<td>–</td>
<td>✓</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>NZAFFQ</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Birmingham IBS</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bowel movement questionnaire</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>PedsQL</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>EPOCH</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>IPAQ</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>ASAQ</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Laboratory</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Matsuda index</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>HbA1c</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fasting lipid profile</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Liver function tests</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>hsCRP and uric acid</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Stool bacteriology</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Gut microbial composition via 16S rRNA amplicon sequencing</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Metagenome</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

ASAQ, Adolescent Sedentary Activity Questionnaire; DXA, dual-energy X-ray absorptiometry; EPOCH, Engagement Perseverance Optimism Connectedness Happiness; HbA1c, glycated haemoglobin; HOMA-IR, homoeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive Protein; IBS, irritable bowel syndrome; IPAQ, International Physical Activity Questionnaire; NZAFFQ, New Zealand Adolescent Food Frequency Questionnaire; PedsQL, Paediatric Quality of Life Inventory.
be recorded on each recipient while seated and after a 5-min rest. Blood pressure will be measured three times, and the median value used for analysis.

In addition, 24-hour ambulatory blood pressure monitoring will be performed at baseline and at 6 weeks, using an oscillometric device (Spacelabs 90217; Spacelabs Medical, Redmond, Washington, USA) on the non-dominant arm. Over a 24-hour period, blood pressure will be measured every 20 min when the recipients are expected to be awake, and every 30 min when they are likely to be asleep (based on self-reported information). Recipients will be asked to record the time they go to bed and the time they wake up over the period of monitoring, so that waking and sleeping times can be more accurately identified.

**Dietary intake**

A dietary record describing all foods and fluids consumed over 3 days will be collected at the 6-week assessment. Recipients will be asked to describe all foods and fluids consumed in detail including brand names, types of foods (eg, low fat) and cooking methods. Quantities will be described using standard household measures, as well as the information from food labels (where appropriate). Recipients will be provided with standardised instructions for completing the dietary record by a trained investigator, who will also review individual records with recipients to clarify errors, omissions, questionable entries or unclear descriptions. These dietary records will be entered into FoodWorks software (V.9.0, Xyris Software, Brisbane, Australia) by a trained investigator.

The New Zealand Adolescent Food Frequency Questionnaire (NZAFFQ) will be administered at baseline and weeks 6, 12 and 26. The NZAFFQ was developed for and validated in New Zealand adolescents aged 14–18 years.

**Physical activity levels**

These will be measured using two questionnaires:

- International Physical Activity Questionnaire (IPAQ): it covers four domains of physical activity, namely work-related, transportation, housework/gardening and leisure time.
- Adolescent Sedentary Activity Questionnaire (ASAQ): it covers a number of sedentary activities across five categories (small screen recreation, education, travel, cultural activities and social activities).

**Health-related quality of life**

This will be assessed using:

- EPOCH Measure of Adolescent Well-Being: it provides an assessment of five positive psychological characteristics (engagement, perseverance, optimism, connectedness and happiness).
- Paediatric Quality of Life Inventory (PedsQL): we will adopt only the teen and young adult self-reports (ie, not the parent proxy), which assess problems over the preceding month relating to physical, emotional, social and school functioning.

In addition, we will assess symptoms of IBS and bowel movements using the Birmingham IBS symptom questionnaire and bowel movements questionnaire, respectively. The Birmingham IBS symptom questionnaire is a self-administered 11-item questionnaire that is scored using the Rome II criteria. The bowel movement questionnaire was designed for this trial to assess and monitor changes pre-treatment and post-treatment.

**Gut microbial composition**

Sample collection will be performed at baseline prior to treatment and at 6 weeks, 12 weeks and 26 weeks post-treatment. Briefly, the participant will be given a bedpan liner (Onelink). They will be asked to: (1) pass urine into the toilet prior to placing the tray on the toilet seat; (2) pass the stools; (3) cover the tray and leave it in the bathroom for immediate collection by a research team member. Using a small spatula, samples will be collected from three different areas of the stool (proximal, middle and distal) and inserted into specimen containers (Onelink). The specimen containers will be immediately placed on ice and taken to the laboratory where they will be frozen and stored at −80°C. DNA and RNA extraction will be completed within 5 days of donation. Time to processing will be recorded.

Note that we will advise participants to try not to have a bowel movement in the morning prior to their visit, having it in the clinic instead. For those participants who are unable to produce a stool sample during their visit, they will be provided with a stool collection kit to take home and detailed instructions on how to collect the stool sample. This kit is made up of: (1) instructions on how to use the stool collection kit; (2) specimen container and (3) bedpan liner. Once the stool has been collected in the home environment, the specimen container should be immediately placed into their home freezer, and kept there until it is delivered to the research team.

All extractions will be performed using Qiagen-AllPrep DNA/RNA mini kit, due to variation in extraction efficiencies with the different kits. However, once the DNA or RNA is extracted and archived, we will have a relatively stable record of the composition and activity of the flora. Frozen faeces (~200 mg; weights will be recorded) will be subsampled from original faecal samples. All DNA and RNA isolations will be performed in a disinfected class II hood at room temperature. Briefly, stool samples will be incubated (10 min, room temperature) with vortexing (30 s ever 2 min) and treated with RLT Plus buffer (1.2 mL; Qiagen) and 12 µL beta-mercaptoethanol (Sigma-Aldrich). Acid-washed glass beads (1 mL; ≤106 µm (−140 US sieve) (Sigma-Aldrich)) will be added to each sample and vortexed (10 min) on a TissueLyzer II (Qiagen). The supernatant will be removed and added to a Qiashredder spin column (Qiagen) and centrifuged (9000 rpm, 2 min, room temperature). The eluent will be added to an AllPrep DNA (Qiagen) spin column and
centrifuged (30s, 14,000 rpm, room temperature). The eluent and AllPrep DNA spin columns will be used for RNA and DNA extraction, respectively, according to the manufacturer’s instructions. Finally, DNA and RNA will be eluted with EB buffer and RNase-free water, respectively, and aliquots stored at −80°C for downstream mixed omics analysis.

A series of blank samples (sterile saline) will be extracted in parallel to sample extractions to enable contamination testing. We will also extract ZymoBIOMICS Microbial Community Standard I (Even, Cellular Mix; Catalog #D6300) to determine potential bias in the extraction process.

For 16S amplicon sequencing, library preparation will be performed using an Illumina platform by a commercial provider (to be determined) using standard protocols for the SV3-4 region. Shotgun metagenomics sequencing will be performed by a commercial provider (to be determined).

All raw sequencing files will be cleaned to remove adapters and primer sequences, and trimmed for sequence quality (Phred score <30).

Longitudinal analysis of gut microbiome data (ie, change in alpha and beta diversity from baseline to 26 weeks in treatment and placebo groups) will be performed on Qime2 (V.2018.4 or later) using default parameters.61 Permutational multivariate analysis of variance (PERMANOVA) and Multivariate Association with Linear Models using MaAsLin (V. 0.0.4; or later)62 will be used to identify any significant differences in gut microbial communities and structure between treatment groups.

Metagenomic sequencing data will be analysed using default parameters of the HMP Unified Metabolic Analysis Network (HuMAnN2) (V2; or later)63 after removal of short reads (minimum length 50 bases, trimmomatic V.0.33 or later64) and human sequences using BMTagger.65 MaAsLin (V.0.0.4; or later)66 will be used to identify significant associations between microbial compositions, metabolomics data and microbial functions.

Safety monitoring
An independent safety monitoring committee has been established. All recipients are advised to remain under supervision in the clinical research unit for 1 hour after initial treatment and we will adopt robust exclusion and screening criteria for donors (as previously described). In addition, recipients’ data will be monitored by the research team and the safety committee throughout the study for any adverse events, in particular, gastrointestinal symptoms and possible allergies. All potential adverse events will be recorded.

If any concerns are identified during screening or clinical assessment of donors or recipients, further clinical evaluation and/or investigation will be immediately undertaken. If concerns are identified during the study, the recipient will be withdrawn if this is thought to be in their best interest.

Outcome measures
Primary outcome
► BMI SDS at 6 weeks.

Secondary outcomes
► BMI SDS at 12 and 26 weeks.
► Total body fat percentage (from DXA) at 6, 12 and 26 weeks.
► Insulin sensitivity at 6, 12 and 26 weeks.
► Gut microbial composition at 6, 12 and 26 weeks.
► Liver function at 6, 12 and 26 weeks.
► Lipid profile at 6, 12 and 26 weeks.
► Inflammatory markers (uric acid, hsCRP) at 6, 12 and 26 weeks.
► Blood pressure at 6, 12 and 26 weeks.
► Health-related quality of life at 6, 12 and 26 weeks.
► IBS symptoms at 6, 12 and 26 weeks.
► Bowel movements at 6, 12 and 26 weeks.

Sample size and power calculation
Power calculation was based on data from a cohort of 50 obese adolescents in Australia aged 14–18 years, with a pooled mean BMI SDS of 2.5 and SD of 0.27 at baseline.66 A study with 32 recipients per group will have 80% power at 5% significance level (two-sided) to detect a group difference of 0.19 in BMI SDS at 6 weeks after gut microbiome transfer, which is equivalent to a difference in weight of approximately 2 kg. To account for an approximate 20% lost to follow-up, we aim to recruit 40 treatment and 40 control recipients.

Data management
All data collected will be entered and stored in password-protected web-based platforms. Rules for data validation will be in place to minimise human error, and all data entered by members of the research team will be double checked by the database administrator to ensure accuracy of stored records. Only the researchers involved in the trial will have access to the final trial dataset.

Statistical analyses
Treatment evaluation will be performed on the principle of intention to treat (ITT), using data collected from all randomised recipients. Baseline demographics and clinical characteristics of recipients will be summarised by randomised group. The distribution of outcome measures will be first evaluated at scheduled visits using descriptive statistics. Generalised linear regression models will be used to assess the main treatment effects between groups, adjusting for the baseline outcome value67 and sex (stratification factor). Model-adjusted estimates and the differences between the two groups will be calculated with 95% CIs. Random effects mixed models will be used to evaluate the outcomes measured repeatedly over time.
time, controlling for correlated data collected from the same recipient. Planned subgroup analysis by sex will be conducted on primary and secondary outcomes to evaluate the consistency of main treatment effects in males and females, by including an interaction term between sex and treatment group in the main model. If a significant interaction effect is found, separate subgroup analyses will be conducted to estimate the treatment effects in specific subgroups.

Missing data on the primary outcome will be imputed using multiple imputations, which create multiple imputed datasets for the incomplete outcome variables that are analysed using some regression models and combined for one inference. The Markov chain Monte Carlo method will be used to produce the parameter estimates, assuming the data are from a multivariate normal distribution and are missing at random. The SAS procedure, PROC MI, will be used which runs 200 iterations of the algorithm before selecting the first completed data set, and then allows 100 iterations between each successive data set. The default minimum number of imputations is 5, and we plan to run 30 to allow for both within and between imputation variances.

Per-protocol analyses will be carried out on those recipients without major protocol violations. A protocol deviation form will be used to record all major protocol deviations, and reviewed in a blinded fashion by the trial steering group prior to final data lock. The per-protocol population will be analysed using same regression models as the primary ITT population to test the robustness of main trial findings.

Our secondary analyses will include the examination of potential effects of diet (eg, fibre intake) and physical activity levels on study outcomes. Data analyses will be performed in SAS V.9.4 (SAS Institute), SPSS V.25 (IBM) and/or Minitab V.16 (Pennsylvania State University, State College, Pennsylvania, USA). All statistical tests will be two sided at $p<0.05$, with no adjustments for multiple comparisons. The CONSORT 2010 guidelines will be followed in reporting the main trial results.

Study status
The recruitment of recipients for the trial began in October 2017. It is expected that the study will be completed in mid-2019.

Patient and public involvement
Public input into the study design was provided in open meetings by the Northern A Health and Disability Ethics Committee, whose membership includes both clinical and lay persons, as well as Māori representatives (New Zealand indigenous people). Information on the trial was subsequently made available on social media platforms (eg, Facebook), which allowed participants to read and contact the researchers if they wanted to participate. Participants were not involved in the development, recruitment of other participants or conduct of the trial. All recipients will be asked about any possible adverse effects of treatment at specific time points throughout the trial; if any serious adverse effects are reported, a thorough follow-up will be conducted to investigate the incident. After completion of data analyses, all recipients will receive information about their individual results.

ETHICS AND DISSEMINATION
Involvement in this trial will be entirely voluntary. If a recipient agrees to take part, they will be free to withdraw from the study at any time. In addition, the participant will be withdrawn if the research team believes their ongoing involvement in the study is not in their best interest. Donors and recipients will be required to provide written informed consent prior to participation in the study. The Ethics Committee requires that a yearly progress report is submitted, which must disclose any protocol violations.

Clinical and biochemical data will be entered into secure databases protected by passwords, with access restricted to investigators. Recipients and caregivers will be informed of incidental findings on unrecognised conditions (eg, diabetes), with further medical follow-up arranged. Importantly, if at the end of the trial we find that gut microbiome transfer leads to a statistically significant improvement in key health outcomes, the treatment will be offered to all recipients who received placebo. Recipients and caregivers will also be provided with information on individual results.

Communication to the scientific community will be through high-profile international research meetings, as well as relevant national and regional meetings. We aim to publish findings in high-impact peer-reviewed international journals. Further, the research team will communicate the findings to the general public in New Zealand and overseas through our institution's Communications Manager. Relevant findings will be shared with the community in a culturally appropriate manner.

Registration details
This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615001351505). In addition, the Universal Trial Number (UTN), WHO, has been obtained (U11111-1176-6753).

Author affiliations
1Liggins Institute, University of Auckland, Auckland, New Zealand
2A Better Start - National Science Challenge, University of Auckland, Auckland, New Zealand
3School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
4School of Sport Exercise and Nutrition, College of Health, Massey University, Auckland, Auckland, New Zealand
5Department of Statistics, The University of Auckland, Auckland, New Zealand
6Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
7Department of Infectious Diseases, Counties Manukau District Health Board, Auckland, New Zealand

Acknowledgements We thank Wendy Ranson, Yara Gerber, and Janene Biggs for their valuable assistance during the development of this trial, and Khan Safayet Hossin for help with the database.


47. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.


